Biotrin Group Announce Research and Development project for Dublin with the Creation of 40 new jobs

Leading-edge Medical Device investment demonstrates Ireland’s reputation as a key Research and Development Location.

Barry O'Leary IDA CEO, Des O'Leary, General Manager Biotrin and Minister for Enterprise, Trade and Innovation Batt O'Keeffe TD

This project is a key element of DiaSorin’s, Biotrin’s parent company, RD&I strategy underpinning developments in automation and molecular diagnostics. The choice to locate this operation in Ireland was based on its strong reputation as an RD&I location and on the success of Biotrin’s existing operation here.  Automated molecular diagnostics is a key part of DiaSorin’s corporate strategy and we look forward to further developing our operations in Ireland as a vital part of this strategy.

Dr. Carlo Rosa, CEO Diasorin

The new project will involve the development of automated molecular diagnostics platform technology and assay reagents for the detection of target DNA and RNA in infectious diseases. It will be based on a new molecular diagnostics technology called loop-mediated isothermal amplification (LAMP). This venture establishes the Dublin site as Diasorin’s Corporate headquarters for Molecular Diagnostics R&D and will bring the total job numbers at the facility to over 100.

Announcing the jobs today, Minister O'Keeffe said the investment 'demonstrates Ireland's attractiveness for leading-edge medical device investments. The development of new diagnostic technologies is the type of high-end activity the Government is eager to support as part of our efforts to build the "smart" economy and innovation island. Ireland has a strong cluster of firms in the life science sector with eight of the top 10 pharmaceutical and 15 of the top 20 medical devices companies based here.
The 40 new jobs will add to our reputation as a global leader for life science firms,' said Minister O'Keeffe.

Dr. Carlo Rosa, CEO Diasorin stated that ‘This project is a key element of DiaSorin’s, Biotrin’s parent company, RD&I strategy underpinning developments in automation and molecular diagnostics. The choice to locate this operation in Ireland was based on its strong reputation as an RD&I location and on the success of Biotrin’s existing operation here.  Automated molecular diagnostics is a key part of DiaSorin’s corporate strategy and we look forward to further developing our operations in Ireland as a vital part of this strategy.’

IDA CEO, Barry O’Leary said, ‘Biotrin’s investment adds to Ireland’s reputation as a global hub for the Life Sciences sector. R&D expansions such as this embed existing operations and pave the way for future investment and job creation.  On behalf of IDA I look forward to working closely with Biotrin as it continues to grow and develop its operations in Ireland.’


About Biotrin
Biotrin was established in Dublin in 1992 to develop and manufacture diagnostic platforms for the clinician and research scientists. Biotrin is the world leader in tests for Human Parvovirus B19, a virus that can cause miscarriage in pregnancy.
Biotrin is based in Dublin, Ireland where it conducts its research and development, manufacturing and marketing activities.  Employment at Biotrin currently stands at 60.
For additional information, please visit our website: www.biotrin.com
or contact  Aoife McNally, Aoife.mcnally@biotrin.ie Tel: + 353 (0) 1 283 1166.


About Diasorin S.p.A
DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 20 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,100 employees, including about 110 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which it operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it
Investor Relations Officer
Laura Villa
DiaSorin S.p.A.
laura.villa@diasorin.it
+39 0161487532
+39 348 15 11 542


IDA Ireland
Thomas McEvoy, Press and PR Manager,
Tel: + 353 (0) 1 603 4255, Mob: +353 (0) 87 7426684

Antoinette Tyrrell, Press Officer,
Tel: +353 (0)1 603 4256, Mob: +353 (0) 87 7572053